Polypeptide compound for preventing and/or treating non-alcoholic steatohepatitis

A technology for peptide compounds and steatohepatitis, applied in the field of biochemistry, can solve the problems such as the listing of targeted therapeutic drugs without NAFLD/NASH, and achieve the effects of low cost, large safety window, and easy to scale up production.

Active Publication Date: 2021-04-09
清远市图微安创科技开发有限公司
View PDF12 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently, there is no targeted tre

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide compound for preventing and/or treating non-alcoholic steatohepatitis
  • Polypeptide compound for preventing and/or treating non-alcoholic steatohepatitis
  • Polypeptide compound for preventing and/or treating non-alcoholic steatohepatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0122]Example 1, Synthesis of Polypeptide Compounds

[0123]material:

[0124]All amino acids were purchased from Novabiochem. If there is no particular explanation, all other reagents are analyzed, purchased from Sigma. PROTEIN TECHNOLOGIES Prelude 6 channel polypeptide synthesizer. PhenomenexLuna C18 Preparation of column (46 mM x 250 mm) was used to purify the polypeptide. High performance liquid chromatographs for Waters products. The mass spectrometry was determined by the Agilent mass spectrometer.

[0125]experimental method:

[0126]The compound was synthesized from the carboxy terminal to the amino terminal direction by the compound of the FMOC solid phase polypeptide, sequentially in sequence in the above amino acid sequence. The specific steps are as follows: First use MBHAR (Amide-Mbha-Resin amide-protected MBHA resin) or king resin, and Dea FMOC protective group synthesis. It is detected with an indengen inspection agent in which the amount of use of the indengenulation reagent is ...

Embodiment 2

[0132]Example 2, Compound 1, Compound 3, Compound 7, Compound 9, Compound 15 and Compound 26 have improved therapeutic effect on MCD-induced mice

[0133]Establishment of the model:

[0134]The test drug: polypeptide compound 1, polypeptide compound 3, polypeptide compound 7, polypeptide compound 9, polypeptide compound 15 and polypeptide compound 26, storage conditions - 20 ° C.

[0135]Modeling: 48 male C57BL / 6J mice, Zhou Ling 8 weeks, provided by the Zhongshan University Experimental Animal Center, randomly divided into 8 groups,: 1) Control group (MCS) + physiological saline, abdominal injection, N = 6; 2) Model group (MCD) + physiological saline, abdominal injection, N = 6; 3) model group (MCD) + 80 μg / kg Compound 1, n = 6; 4) model group (MCD) + 80 μg / Kg Compound 3, N = 6; 5) Model Group (MCD) + 80 μg / kg Compound 7, N = 6; 6) Model Group (MCD) + 80 μg / kg Compound 9, N = 6; 7) Model Group (MCD) + 80 μg / kg Compound 15, N = 6; 8) Model Group (MCD) + 80 μg / kg Compound 26, N ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a polypeptide compound for treating and/or preventing non-alcoholic steatohepatitis. The polypeptide compound has the characteristics of high biological activity, no adverse reaction and the like, and can obviously inhibit lipid deposition in liver and improve fatty liver and inflammatory degree. The polypeptide compound can be used for preparing medicines for preventing and/or treating non-alcoholic steatohepatitis.

Description

Technical field[0001]The present invention belongs to the field of biochemical techniques, and in particular, to a polypeptide compound for preventing and / or treating non-alcoholic fatty hepatitis (NASH).Background technique[0002]Fatty Liver is a common liver pathological change in the liver phenotycosis caused by various causes. Normal human liver tissue contains 2% to 4% of the liver, wherein the phospholipid accounts for more than 50%, and triglyceride (Tg) accounts for 20%, free fatty acid (FFA) accounts for 20%, and cholesterol accounts for about 7%. The rest are cholesterol esters. If the lipid accumulation of hepatic cells exceeds the liver weight 5% or more of the tissue per unit area of ​​1 / 3 or more hepatocyte fat, it is called fatty liver (Fan Jian Gao, Zeng Middle-German. Advances in fatty liver [J] Diseases and Liver Diseases, 1999 (02): 3-5.). According to the causes of the disease of fatty liver, it is divided into Alcoholic Fatty Liver Disease (FALD) and non-Alcoho...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/00A61K38/16A61P1/16
CPCC07K14/00A61P1/16A61K38/00
Inventor 刘琦张斌智
Owner 清远市图微安创科技开发有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap